Ipodate sodium

From Wikipedia, the free encyclopedia

Ipodate sodium
Systematic (IUPAC) name
sodium 3-[3-(dimethylaminomethylideneamino)-2,4,6-triiodophenyl]propanoate
Identifiers
CAS number	5587-89-3
ATC code	?
PubChem	23671932
Chemical data
Formula	C12H12I3N2NaO2
Mol. mass	619.93906 g/mol
SMILES	eMolecules & PubChem
Physical data
Melt. point	168-169 °C (-104 °F)
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Intravenous

Ipodate sodium is an iodine-containing radiopaque contrast media used for X-rays. The drug is given intravenously and the resulting contrast allows for easy resolution of the blood vasculature. The drug goes by the trade name Oragrafin.

Contents 1 Other uses 1.1 Grave's Disease 1.2 Thyroid Storm 2 References

[edit] Other uses

Although not FDA approved, sodium ipodate has been used to treat Graves' Disease and Thyroid Storm, an extreme form of hyperthyroidism.

[edit] Grave's Disease

One study done by the Journal of Clinical Endocrinology & Metabolism^[1] showed that long-term treatment of Grave's disease with ipodate sodium (500 mg daily) reduced levels of T3 and T4 in the patients. This was done with minimal side effects, indicating possible clinical usefulness. Radioactive iodine treatment was also not effected, indicating concurrent usage with ipodate is feasible.

[edit] Thyroid Storm

In emergency situations, ipodate can be administered for thyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring the T3 and T4 levels back down. It is not considered a first-line approach, as potassium iodide and beta blockers have less potential for side-effects as well as FDA approval.

[edit] References